Online ISSN: 2515-8260

Keywords : Lipid profile

Determination of cardiovascular autonomic neuropathy in type II DM patients

Amit Varshney; Vidya Sagar Ram; Kanhaiya Prasad

European Journal of Molecular & Clinical Medicine, 2020, Volume 7, Issue 10, Pages 3788-3792

Background: The diabetic neuropathy, including the cardiovascular autonomic neuropathy
(CAN), is a common complication of type 1 and 2 diabetes that leads to high mortality and
morbidity. The present study was conducted to determine CAN in type II DM patients.
Materials & Methods: 168 type II DM patients of both genders were recruited. Resting
heart rate, blood pressure, and body mass index (BMI), systolic blood pressure (SBP) ≥140
mmHg or diastolic blood pressure (DBP) ≥90 mmHg, fasting lipid profile (low-density
lipoprotein/LDL, high-density lipoprotein/HDL, triglycerides/TG) and cardiac autonomic
function was evaluated with the CAN system analyzer as early, definite and advanced
Results: CAN was seen in 66 patients. The mean age (years) was 45.2 and 44.5, duration of
diabetes (years) was 6.1 and 12.3, SBP (mm Hg) was 130.4 and 134.5, DBP (mm Hg) was
86.2 and 87.6, resting heart rate (beats/min) was 76.3 and 87.4, LDL (mg/dl) was 102.4 and
98.6, HDL (mg/dl) was 40.5 and 38.1 and TG (mg/dl) was 165.2 and 184.6 in CAN- and
CAN+ patients. The difference was non- significant (P> 0.05). Severity of CAN found to be
early in 20%, definitive in 45% and advanced in 35%. The difference was significant (P<
Conclusion: Type II diabetes patients had high prevalence of cardiac autonomic

The Effect Of Highly Active Antiretroviral Therapyon Lipid Profileof Hiv Patients

Vera Bahar; Andi Makbul Aman; Sudirman Katu; Syakib Bakri; Haerani Rasyid; Husaini Umar; Risna Halim; Arifin Seweng

European Journal of Molecular & Clinical Medicine, 2020, Volume 7, Issue 8, Pages 953-960

Background:The widespread use of highly active retroviral therapy (HAART) has indicated a dramatic reduction in impairment due to immunodeficiency. Several studies have shown that an adverse event of HAART on dyslipidemia and insulin resistance. This study aimed to assess changes in lipid profiles after HAART.
Methods:A prospective cohort study with a consecutive sampling method consists of 59 HIV-infected patientsreceiving HAART at Dr. Wahidin Sudirohusodo Hospital, Makassar, Indonesia, from March-September 2020. Lipid profiles were measured at the initial time and after three months of HAART. The drug regimen was divided into two groups: Regimen 
group 1 (tenofovir, lamivudine, efavirenz), and another regimen group (consist of 4 regimen group combination: zidovudine, lamivudine, efavirenz; tenofovir, emtricitabine, lopinavir/ritonavir; tenofovir, lamivudine, nevirapine, and tenofovir, lamivudine, rilpivirine). ANOVA paired t-test and chi-square test were used for statistical analysis(it is significant if p is<0.05).
Results:The mean age of the subjects was 32.1 ± 6.6 years old. About 76.3% of subjects were male. Regimen 1 was used by 88.1% of the subjects and another regimen only 11.9% of the subjects. There were 27 subjects (45.8%) were underweight. The proportion of subjects with lipid abnormalities after 3 months of HAART significantly higher in LDL-c and TG level (P= 0.002 and 0.021). Regimen group1 showed increased levels of total cholesterol (TC), LDL-c, and TG (P = 0.037, 0.041, and 0.001) after HAART.
Conclusion:Highly active retroviral therapy is associated with lipid profile changes in HIV patients after 3 months of therapy.

Lipid Profile Between Epileptic Patients With Cyp-450 Enzyme Inducer Versus Cyp-450 Enzyme Inhibitor As A Monotherapy Anti Epileptic Drug: A Comparative Study

Susi Aulina; Audry Devisanty Wuysang; Andi Kurnia Bintang; Yudy Goysal; Fransiska Carmelia Subeno

European Journal of Molecular & Clinical Medicine, 2020, Volume 7, Issue 7, Pages 1123-1130

Treatment of epilepsy is often a lifetime. Several studies report the effect of anti epileptic drug (AED) to lipid profile. This study aims to assess the differences of lipid profile of epileptic patients receiving CYP-450 enzyme inducer and inhibitor monotherapy AED.
This study was conducted in cross-sectional terms with consecutive sampling, from June-October 2019, at Wahidin Sudirohusodo Regional Hospital, Hasanuddin University Hospital, and private practice. The independent variable were AEDs, consist of phenytoin, phenobarbital, carbamazepine, or valproic acid, while the dependent one was the lipid profile. Thirty-five samples were obtained using CYP-450 enzyme inducer AED, consisted of 11 samples using phenytoin, 11 samples using phenobarbital, 13 samples using carbamazepine, and 16 samples using CYP-450 enzyme inhibitor AED (valproic acid).
The results showed higher level of total cholesterol, Low Density Lipoprotein (LDL), and High Density Lipoprotein (HDL) in the CYP-450 enzyme inducer AED group than the CYP-450 inhibitor one; there was no difference of triglyceride (TG) level, while higher level was shown in the CYP-450 enzyme inducer AED group.



European Journal of Molecular & Clinical Medicine, 2020, Volume 7, Issue 7, Pages 2104-2112

Background: PCOS is the most common endocrinological disorder affecting 6 -14% amongst reproductive age group. The pathophysiology of PCOS is complex and it is still not well understood. Many markers have been studied to correlate between homocysteine level and other clinical, metabolic and hormonal profile. Preliminary investigations indicate that in women with PCOS, serum biomarkers of cardiovascular disorders such as homocysteine are abnormal. Furthermore the interactions between homocysteine and PCOS, biochemical features such as obesity, insulin resistance and higher levels of androgen, have been researched and the potential determinant of this finding is still being explored.
Aim and Objectives: We aim to determine association between hyperhomocysteinemia and PCOS. The objectives of this study is to evaluate and compare clinical, metabolic and 
hormonal profile in women of PCOS with normal homocysteine level with that of increased homocysteine level.
Materials and Methods: This is a prospective observational study which will be performed in the department of obstetrics and gynaecology, AVBRH, DMIMS (Deemed to be University, Wardha), a tertiary care teaching hospital situated in the rural area of Wardha district in over 140 patients for period between 2020-22. This study will include PCOS patients based on Rotterdam diagnostic criteria and will exclude patients with known metabolic, cardiovascular and endocrine disorders. Metabolic and hormonal profile will be evaluated with BMI, Lipid profile, Insulin resistance, serum levels of LH, FSH, DHEA and Testosterone in all patients. Serum homocysteine levels will be measured using ELISA.
Expected Results: We expect that there will be significant difference in clinical, metabolic and hormonal profile of PCOS women having hyperhomocysteinemia than women having normal homocysteine level.